B2M and B-cell chronic lymphocytic leukemia: Here we show that B2M plasma levels but not the CLL-IPI retain their prognostic value in Binet stage A CLL patients with compromised kidney function diagnosed in both treatment eras of chemoimmunotherapy and targeted agents.